Malignant mast cell neoplasm Recruiting Phase 2 Trials for Avapritinib (DB15233)

Also known as: Malignant Mast Cell Tumors / Leukemia, Mast Cell / Mast Cell Leukemia / Mast Cell Leukemia (MCL) / Malignant-mast cell tumours / Aggressive systemic mastocytosis / Mast-Cell Sarcoma

IndicationStatusPhase
DBCOND0007107 (Malignant mast cell neoplasm)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03580655(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisTreatment